The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat

Nephron - Experimental Nephrology

Volumn 108, Issue 2, 2008, Pages

  Wittmann, Sandra ^a   Daniel, Christoph ^a   Braun, Andrea ^a   Vogelbacher, Regina ^a   Shimizu, Fuijo ^b   Kawachi, Hiroshi ^b   Hugo, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Chronic kidney disease; Everolimus; Matrix deposition; mTOR inhibitor; Vascular endothelial growth factor

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CHRONIC DISEASE; GLOMERULONEPHRITIS; ISOANTIBODIES; MALE; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TIME FACTORS;

EID: 40449083541     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000116112     Document Type: Article

References (41)

1. Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH: SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42.
2. Nashan B: Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002;11:1845-1857.
3. Sehgal SN, Camardo JS, Scarola JA, Maida BT: Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens 1995;4:482-487.
4. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E: Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-220.
5. Butani L: Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004;78:1362-1366.
6. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM: Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4:1869-1875.
7. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, Wochos DN, Synhavsky A, Hippler S, Larson TS, Bagniewski SM, Velosa JA: Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004;19:1288-1292.
8. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C: Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005;5:2849-2861.
9. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP: Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000;8:52-62.
10. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-492.
11. Wang W, Chan YH, Lee W, Chan L: Effect of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 2001;33:1036-1037.
12. Kawachi H, Oite T, Shimizu F: Quantitative study of mesangial injury with proteinuria induced by monoclonal antibody 1-22-3. Clin Exp Immunol 1993;92:342-346.
13. Shimizu F, Kawachi H, Orikasa M: Role of mesangial cell damage in progressive renal disease. Kidney Blood Press Res 1999;22:5-12.
14. Kawachi H, Orikasa M, Matsui K, Iwanaga T, Toyabe S, Oite T, Shimizu F: Epitope-specific induction of mesangial lesions with proteinuria by a MoAb against mesangial cell surface antigen. Clin Exp Immunol 1992;88:399-404.
15. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007;30:253-259.
16. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, Johnson RJ: A new model of renal microvascular endothelial injury. Kidney Int 1997;52:182-194.
17. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, Johnson RJ: Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995;147:1715-1727.
18. Hugo C, Hugo C, Pichler R, Gordon K, Schmidt R, Amieva M, Couser WG, Furthmayr H, Johnson RJ: The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. J Clin Invest 1996;97:2499-2508.
19. Matsui K, Nagy-Bojarsky K, Laakkonen P, Krieger S, Mechtler K, Uchida S, Geleff S, Kang DH, Johnson RJ, Kerjaschki D: Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopeptidase p and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J Am Soc Nephrol 2003;14:1981-1989.
20. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-1447.
21. Daniel C, Pippin J, Shankland SJ, Hugo C: The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1. Lab Invest 2004;84:588-596.
22. Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ: Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998;53:302-311.
23. Johnson RJ: The glomerular response to injury: progression or resolution? Kidney Int 1994;45:1769-1782.
24. Riley SG, Steadman R, Williams JD, Floege J, Phillips AO: Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes. J Lab Clin Med 1999;134:304-312.
25. Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, Rupprecht H, Imai E, Hugo C: Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003;163:1185-1192.
26. Yan M, Schneider J, Gear R, Lu F, LaDow K, Warshawsky D, Heffelfinger SC: Expression of angiogenic factors is upregulated in DMBA-induced rat mammary pathologies. Pathobiology 2004;71:253-260.
27. Ruiz V, Ordonez RM, Berumen J, Ramirez R, Uhal B, Becerril C, Pardo A, Selman M: Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;285:L1026-L1036.
28. Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF: Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 2006;69:2013-2021.
29. Rangan GK: Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 2006;29:1153-1161.
30. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F: Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006;21:3252-3257.
31. Fox R, Nhan TQ, Law GL, Morris DR, Liles WC, Schwartz SM: PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. EMBO J 2007;26:505-515.
32. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
33. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63:917-926.
34. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS: Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-F706.
35. Eremina V, Quaggin SE: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004;13:9-15.
36. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-716.
37. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J: VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999;104:913-923.
38. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001;159:599-608.
39. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, Nagata M, Watanabe T, Fan J: Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007;18:2094-2104.
40. Hermann P, Poschmann G, Bolliger S, Meyer D, Schuurman HJ: Mercuric chloride-induced glomerulopathy in BN-rats: application to preclinical drug testing. Transplant Proc 1993;25:2826-2827.
41. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063-2072.